Julien Cherfils‐Vicini

2.7k total citations · 2 hit papers
22 papers, 1.8k citations indexed

About

Julien Cherfils‐Vicini is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Julien Cherfils‐Vicini has authored 22 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 6 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Julien Cherfils‐Vicini's work include Immune Cell Function and Interaction (9 papers), Immune Response and Inflammation (6 papers) and Immune cells in cancer (5 papers). Julien Cherfils‐Vicini is often cited by papers focused on Immune Cell Function and Interaction (9 papers), Immune Response and Inflammation (6 papers) and Immune cells in cancer (5 papers). Julien Cherfils‐Vicini collaborates with scholars based in France, United States and Malaysia. Julien Cherfils‐Vicini's co-authors include Isabelle Cremer, Wolf H. Fridman, Catherine Sautès‐Fridman, Diane Damotte, Marie‐Caroline Dieu‐Nosjean, Éric Gilson, Pierre Validire, Vincent Vieillard, Éric Vivier and Marco Alifano and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Julien Cherfils‐Vicini

19 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells

2014 462 citations Antoine Marçais, Julien Cherfils‐Vicini et al. Nature Immunology profile →
Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-β activation

2023 148 citations Isabelle Bourget, Pascal Lopez et al. Cancer Cell profile →

Peers

Countries citing papers authored by Julien Cherfils‐Vicini

Since Specialization

Citations

This map shows the geographic impact of Julien Cherfils‐Vicini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julien Cherfils‐Vicini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julien Cherfils‐Vicini more than expected).

Fields of papers citing papers by Julien Cherfils‐Vicini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julien Cherfils‐Vicini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julien Cherfils‐Vicini. The network helps show where Julien Cherfils‐Vicini may publish in the future.

Co-authorship network of co-authors of Julien Cherfils‐Vicini

This figure shows the co-authorship network connecting the top 25 collaborators of Julien Cherfils‐Vicini. A scholar is included among the top collaborators of Julien Cherfils‐Vicini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julien Cherfils‐Vicini. Julien Cherfils‐Vicini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The ganglioside GD3 and its synthase (ST8SIA1) as novel senescence markers associated with osteoarthritis 2025 ·GeroScience ·(unknown), (unknown), (unknown), (unknown), Benoît Guibert, Louis Dagneaux, (unknown), Thérèse Commes, Éric Gilson, Christian Jørgensen, Julien Cherfils‐Vicini, Yves‐Marie Pers, Jean‐Marc Brondello	0
2	Activated B-Cells enhance epitope spreading to support successful cancer immunotherapy 2024 ·Frontiers in Immunology ·(unknown), Nicolas Leulliot, Julien Cherfils‐Vicini, Magali Blaud, Patrick Brest	2
3	Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-β activation breakdown → 2023 ·Cancer Cell ·(unknown), (unknown), Isabelle Bourget, Pascal Lopez, (unknown), Julien Cherfils‐Vicini, Chloé Dominici, Géraldine Rios, (unknown), Bodu Liu, David L. Spector, Sidse Ehmsen, Shufang Renault, Caroline Hego, Fatima Mechta‐Grigoriou, François‐Clément Bidard, Mikkel G. Terp, Mikala Egeblad, Cédric Gaggioli, Jean Albrengues	148
4	A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy 2021 ·Nature Communications ·Laëtitia Douguet, (unknown), Jonathan Benzaquen, Laetitia Seguin, Thierry Juhel, Xavier Dezitter, Christophe Duranton, Bernhard Ryffel, Jean Kanellopoulos, Cécile Delarasse, Nicolas Renault, Christophe Furman, (unknown), Chloé C. Féral, Julien Cherfils‐Vicini, Régis Millet, Sahil Adriouch, Alina Ghinet, Paul Hofman, Valérie Vouret‐Craviari	64
5	A Novel Screen for Expression Regulators of the Telomeric Protein TRF2 Identified Small Molecules That Impair TRF2 Dependent Immunosuppression and Tumor Growth 2021 ·Cancers ·(unknown), (unknown), Cédric Gaggioli, (unknown), Nicole Wagner, Jing Ye, Pierre Jalinot, Julien Cherfils‐Vicini, Éric Gilson	14
6	Les horloges de la longévité 2020 ·médecine/sciences ·Julien Cherfils‐Vicini, Éric Gilson	0
7	Inhibiting TRF 1 upstream signaling pathways to target telomeres in cancer cells 2019 ·EMBO Molecular Medicine ·Julien Cherfils‐Vicini, Éric Gilson	9
8	Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF 2 2019 ·The EMBO Journal ·Julien Cherfils‐Vicini, (unknown), (unknown), (unknown), Olivier Croce, (unknown), Balázs Győrffy, (unknown), Valérie M. Renault, (unknown), Carlo Leonetti, Pasquale Zizza, Fabrice Allain, François Ghiringhelli, (unknown), Marina Shkreli, Éric Vivier, Annamaria Biroccio, Éric Gilson	49
9	Nitric Oxide Synthase 2 Improves Proliferation and Glycolysis of Peripheral γδ T Cells 2016 ·PLoS ONE ·Laëtitia Douguet, Julien Cherfils‐Vicini, Lloyd Bod, Renée Lengagne, Éric Gilson, Armelle Prévost‐Blondel	11
10	Genetic and Pharmacological Inactivation of the Purinergic P2RX7 Receptor Dampens Inflammation but Increases Tumor Incidence in a Mouse Model of Colitis-Associated Cancer 2015 ·Cancer Research ·Paul Hofman, Julien Cherfils‐Vicini, (unknown), Marius Ilié, Thierry Juhel, Xavier Hébuterne, Éric Gilson, Annie Schmid‐Alliana, Olivier Boyer, Sahil Adriouch, Valérie Vouret‐Craviari	96
11	TLR7 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Non–Small Cell Lung Cancer 2014 ·Cancer Research ·(unknown), Lucile Crozet, Diane Damotte, Kristina Iribarren, Catherine Schramm, Marco Alifano, Audrey Lupo, Julien Cherfils‐Vicini, Jérémy Goc, Sandrine Katsahian, (unknown), Marie‐Caroline Dieu‐Nosjean, Wolf H. Fridman, Catherine Sautès‐Fridman, Isabelle Cremer	88
12	The Wilms’ tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression 2014 ·Nature Communications ·Kay‐Dietrich Wagner, Julien Cherfils‐Vicini, Naoki Hosen, Peter Hohenstein, Éric Gilson, Nicholas D. Hastie, Jean‐François Michiels, Nicole Wagner	65
13	The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells breakdown → 2014 ·Nature Immunology ·Antoine Marçais, Julien Cherfils‐Vicini, Charlotte Viant, Sophie Degouve, Sébastien Viel, Aurore Fenis, (unknown), Katia Mayol, (unknown), Jacques Bienvenu, Yann‐Gaël Gangloff, Éric Gilson, Éric Vivier, Thierry Walzer	462
14	A novel pathway links telomeres to NK-cell activity 2014 ·OncoImmunology ·Julien Cherfils‐Vicini, Pasquale Zizza, Éric Gilson, Annamaria Biroccio	6
15	Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma 2011 ·Cancer Research ·(unknown), Julien Cherfils‐Vicini, Diane Damotte, Lucile Crozet, Vincent Vieillard, Pierre Validire, Pascale André, Marie‐Caroline Dieu‐Nosjean, Marco Alifano, Jean‐François Régnard, Wolf H. Fridman, Catherine Sautès‐Fridman, Isabelle Cremer	381
16	Tumor microenvironment is multifaceted 2011 ·Cancer and Metastasis Reviews ·Catherine Sautès‐Fridman, Julien Cherfils‐Vicini, Diane Damotte, Sylvain Fisson, Wolf H. Fridman, Isabelle Cremer, Marie‐Caroline Dieu‐Nosjean	91
17	Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance 2010 ·Journal of Clinical Investigation ·Julien Cherfils‐Vicini, (unknown), (unknown), Ludivine Laurans, Pierre Validire, (unknown), Pierre Magdeleinat, Fathia Mami‐Chouaib, Marie‐Caroline Dieu‐Nosjean, Wolf H. Fridman, Diane Damotte, Catherine Sautès‐Fridman, Isabelle Cremer	181
18	Cancer pulmonaire 2010 ·médecine/sciences ·Julien Cherfils‐Vicini, Diane Damotte, Wolf H. Fridman, Catherine Sautès‐Fridman, Isabelle Cremer	4
19	Characterization of immune functions in TRAF4‐deficient mice 2008 ·Immunology ·Julien Cherfils‐Vicini, Benoît Vingert, Audrey Varin, Éric Tartour, Wolf H. Fridman, Catherine Sautès‐Fridman, Catherine H. Régnier, Isabelle Cremer	23
20	NKG2C is a major triggering receptor involved in the Vδ1 T cell-mediated cytotoxicity against HIV-infected CD4 T cells 2008 ·AIDS ·Hugues Fausther‐Bovendo, Nadia Wauquier, Julien Cherfils‐Vicini, Isabelle Cremer, Patrice Debré, Vincent Vieillard	55

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact